Evidence map›Paper›PMID 31202577›Full record

ArticleMolecular cell2019

Topoisomerase II-Induced Chromosome Breakage and Translocation Is Determined by Chromosome Architecture and Transcriptional Activity.

Andres Canela, Yaakov Maman, Shar-Yin N Huang, Gordana Wutz, Wen Tang, Guido Zagnoli-Vieira, Elsa Callen, Nancy Wong, Amanda Day, Jan-Michael Peters and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 134 papers.

0numbers the graph read from it
0cells of the map it votes in
134citing papers in PubMed
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

134 citing papers in PubMed, 212 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. PDS5A and TOP2B cooperate for chromatin recruitment via CTCF.bioRxiv : the preprint server for biology · 2026
    Article
  9. Article
  10. Article
  11. Review
  12. Asymmetrical recognition and processing of double-strand breaks formed during DNA replication.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

74 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 5 countries.

Andres CanelaLaboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA; The Hakubi Center for Advanced Research and Radiation Biology Center, Graduate School of Biostudies, Kyoto University, Kyoto, Japan.
Yaakov MamanLaboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA.
Shar-Yin N HuangDevelopmental Therapeutics Branch and Laboratory of Molecular Pharmacology, NIH, Bethesda, MD, USA.
Gordana WutzResearch Institute of Molecular Pathology, Vienna Biocenter, Vienna, Austria.
Wen TangResearch Institute of Molecular Pathology, Vienna Biocenter, Vienna, Austria.
Guido Zagnoli-VieiraGenome Damage and Stability Centre, University of Sussex, Falmer, Brighton BN1 9RQ, UK.
Elsa CallenLaboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA.
Nancy WongLaboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA.
Amanda DayLaboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA.
Jan-Michael PetersResearch Institute of Molecular Pathology, Vienna Biocenter, Vienna, Austria.
Keith W CaldecottGenome Damage and Stability Centre, University of Sussex, Falmer, Brighton BN1 9RQ, UK; Department of Genome Dynamics, Institute of Molecular Genetics of the Czech Academy of Sciences, 142 20 Prague, 4, Czech Republic.
Yves PommierDevelopmental Therapeutics Branch and Laboratory of Molecular Pharmacology, NIH, Bethesda, MD, USA.
André NussenzweigLaboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA. Electronic address: andre_nussenzweig@nih.gov.
National Human Genome Research Institute · USNational Cancer Institute · USNational Institutes of Health · USResearch Institute of Molecular Pathology · ATUniversity of Sussex · GBVienna Biocenter · AT

Funding

DNA RepairZIABC010283 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI NUSSENZWEIG, ANDRE A. · 2009 to 2025
$27.0M
Relationship between DNA damage detection and signalingZIABC010959 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI NUSSENZWEIG, ANDRE A. · 2009 to 2025
$27.0M
DNA TOPOISOMERASES AS TARGET OF ACTION OF ANTICANCER DRUGSZ01BC006161 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI POMMIER, YVES · 1996 to 2008
$1.5M
Cancer Research UK 16771Cancer Research UK 27322European Research Council 693949Intramural NIH HHS Z01 BC006161Intramural NIH HHS ZIA BC010283Intramural NIH HHS ZIA BC010959
6 · The paper itself

Abstract

Topoisomerase II (TOP2) relieves torsional stress by forming transient cleavage complex intermediates (TOP2ccs) that contain TOP2-linked DNA breaks (DSBs). While TOP2ccs are normally reversible, they can be "trapped" by chemotherapeutic drugs such as etoposide and subsequently converted into irreversible TOP2-linked DSBs. Here, we have quantified etoposide-induced trapping of TOP2ccs, their conversion into irreversible TOP2-linked DSBs, and their processing during DNA repair genome-wide, as a function of time. We find that while TOP2 chromatin localization and trapping is independent of transcription, it requires pre-existing binding of cohesin to DNA. In contrast, the conversion of trapped TOP2ccs to irreversible DSBs during DNA repair is accelerated 2-fold at transcribed loci relative to non-transcribed loci. This conversion is dependent on proteasomal degradation and TDP2 phosphodiesterase activity. Quantitative modeling shows that only two features of pre-existing chromatin structure-namely, cohesin binding and transcriptional activity-can be used to predict the kinetics of TOP2-induced DSBs.

Indexed as

DNA Breaks, Double-StrandedChromosome BreakageChromosomesDNADNA-Binding ProteinsDNA RepairDNA Topoisomerases, Type IIEtoposideGene ConversionHCT116 CellsHumansKineticsMultiprotein ComplexesPoly-ADP-Ribose Binding ProteinsTopoisomerase II InhibitorsTorsion, MechanicalDNADNA-Binding ProteinsDNA Topoisomerases, Type IIEtoposideMultiprotein ComplexesPoly-ADP-Ribose Binding ProteinsTOP2A protein, humanTopoisomerase II Inhibitors3D chromatin organizationchromosomal translocationscohesinDNA double-strand breaksproteasomequantitative modelingTDP2topoisomerasetopoisomerase 2 cleavage complextranscription

Identifiers

PMID31202577
PMCPMC8170508
OpenAlexW2949696308

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.